Jaffetilchin Investment Partners LLC Has $1.92 Million Holdings in Baxter International Inc. (NYSE:BAX)

Jaffetilchin Investment Partners LLC boosted its position in Baxter International Inc. (NYSE:BAX - Free Report) by 115,259.6% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 65,755 shares of the medical instruments supplier's stock after purchasing an additional 65,698 shares during the period. Jaffetilchin Investment Partners LLC's holdings in Baxter International were worth $1,917,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of BAX. Bank of New York Mellon Corp lifted its position in shares of Baxter International by 22.3% during the fourth quarter. Bank of New York Mellon Corp now owns 15,359,040 shares of the medical instruments supplier's stock worth $447,870,000 after acquiring an additional 2,803,920 shares in the last quarter. Geode Capital Management LLC grew its position in Baxter International by 2.4% during the fourth quarter. Geode Capital Management LLC now owns 12,446,939 shares of the medical instruments supplier's stock valued at $362,006,000 after acquiring an additional 290,279 shares during the last quarter. Thompson Siegel & Walmsley LLC lifted its stake in Baxter International by 35.1% in the fourth quarter. Thompson Siegel & Walmsley LLC now owns 2,548,215 shares of the medical instruments supplier's stock worth $74,306,000 after purchasing an additional 662,042 shares during the last quarter. Sound Shore Management Inc. CT bought a new position in Baxter International during the 4th quarter worth approximately $72,450,000. Finally, Russell Investments Group Ltd. raised its holdings in Baxter International by 40.4% during the 4th quarter. Russell Investments Group Ltd. now owns 1,745,709 shares of the medical instruments supplier's stock valued at $50,904,000 after buying an additional 502,370 shares during the last quarter. 90.19% of the stock is currently owned by institutional investors.

Baxter International Trading Up 1.5 %

NYSE BAX traded up $0.43 during trading hours on Wednesday, reaching $28.23. The company had a trading volume of 2,289,219 shares, compared to its average volume of 4,501,441. The company has a current ratio of 1.43, a quick ratio of 1.09 and a debt-to-equity ratio of 1.31. Baxter International Inc. has a 1-year low of $26.25 and a 1-year high of $41.18. The stock has a market capitalization of $14.48 billion, a P/E ratio of -22.05, a price-to-earnings-growth ratio of 0.93 and a beta of 0.64. The stock has a 50-day moving average of $32.61 and a 200 day moving average of $32.81.

Baxter International (NYSE:BAX - Get Free Report) last announced its earnings results on Thursday, February 20th. The medical instruments supplier reported $0.58 earnings per share for the quarter, topping the consensus estimate of $0.52 by $0.06. The business had revenue of $2.75 billion during the quarter, compared to the consensus estimate of $2.67 billion. Baxter International had a negative net margin of 5.05% and a positive return on equity of 16.67%. As a group, research analysts anticipate that Baxter International Inc. will post 2.48 earnings per share for the current fiscal year.

Baxter International Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, April 1st. Investors of record on Friday, February 28th were given a dividend of $0.17 per share. This represents a $0.68 annualized dividend and a yield of 2.41%. The ex-dividend date was Friday, February 28th. Baxter International's dividend payout ratio (DPR) is presently -53.13%.

Analyst Ratings Changes

BAX has been the subject of several research reports. Barclays increased their target price on Baxter International from $39.00 to $41.00 and gave the stock an "overweight" rating in a research report on Monday, March 10th. Argus upgraded Baxter International from a "hold" rating to a "buy" rating in a research report on Monday, February 24th. JPMorgan Chase & Co. decreased their target price on Baxter International from $38.00 to $36.00 and set a "neutral" rating on the stock in a report on Friday, February 21st. Finally, The Goldman Sachs Group started coverage on shares of Baxter International in a research note on Wednesday, February 26th. They issued a "buy" rating and a $42.00 price objective for the company. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $38.56.

Baxter International Company Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.